FDA Expands Approval for Johnson and Johnson Drug
The U.S. Food and Drug Administration approved the expanded use of Johnson and Johnson's drug Imaavy for warm autoimmune hemolytic anemia. The treatment is cleared for patients aged 12 and older who have previously been treated with steroids.
Xurve View
Insights:
Xurve View
The United States Food and Drug Administration expanded approval for JOHNSON & JOHNSON's drug Imaavy to treat warm autoimmune hemolytic anemia on Monday morning. The decision makes Imaavy the first cleared therapy for the rare blood disorder in patients aged 12 and older. The approval opens a new revenue stream for the health care giant in a market with limited specialized options.
